Prognostic Performance of the Residual Cancer Burden Index With Respect to Molecular Breast Cancer Subtypes

Key Points

• Residual cancer burden index serves as a significant prognostic marker in breast cancer, indicating survival outcomes post-chemotherapy.
• Key evidence shows positive correlations between RCB scores and prognosis across different breast cancer subtypes during treatment.
• Observational analysis evaluated RCB's prognostic performance in various molecular breast cancer subtypes receiving neoadjuvant chemotherapy.
• Findings suggest that RCB could enhance prognostic strategies for individualized treatment plans in breast cancer management.